• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC MEXICO S. DE R.L. DE CV COREVALVE TRANSCATHETER AORTIC VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC MEXICO S. DE R.L. DE CV COREVALVE TRANSCATHETER AORTIC VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV Back to Search Results
Model Number MCS-P4-23-AOA
Medical Device Problem Codes Gradient Increase (1270); Device Stenosis (4066)
Health Effect - Clinical Codes Dyspnea (1816); Fatigue (1849); Peripheral Edema (4578); No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 07/08/2025
Type of Reportable Event Serious Injury
Event or Problem Description
It was reported approximately ten and a half years following implant of a medtronic transcatheter aortic bioprosthetic valve (tav), valve failure was noted.The primary mode of valve failure was structural valve deterioration; predominant aortic stenosis with severe hemodynamic valve deterioration.This was characterized by an increase in mean gradient >=20mm hg from baseline and mean gradient >=30mm hg.The patient was enrolled in a clinical study with existing, baseline valve failure to determine whether a redo-transcatheter aortic valve replacement procedure, tav-in-tav, was appropriate.Approximately two months, three weeks after the valve failure was noted, the patient was treated with re-intervention for the failed tav.A non-medtronic (edwards) valve was implanted within the medtronic tav.No patient complications were reported as a result of this event.
 
Additional Manufacturer Narrative
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
 
Additional Manufacturer Narrative
Updated data: b2, b5, h6 medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
 
Event or Problem Description
Additional information received that prior to the valve-in-valve revision the patient experienced fatigue, shortness of breath, and lower extremity swelling.Hospitalization was required as result of the valve-in-valve revision.The patient was discharged 2 days following admission.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
COREVALVE TRANSCATHETER AORTIC VALVE
Common Device Name
AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV
Manufacturer (Section D)
MEDTRONIC MEXICO S. DE R.L. DE CV
av. paseo del cucapah #10510
tijuana,bc 22210
MX  22210
Manufacturer (Section G)
MEDTRONIC MEXICO S. DE R.L. DE CV
av. paseo del cucapah #10510
tijuana,bc 22210
MX   22210
Manufacturer Contact
alison sweeney
parkmore business park west
galway 
EI  
091708096
MDR Report Key23417842
Report Number9617601-2025-02383
Device Sequence Number10381079
Product Code NPT
UDI-Device Identifier00643169430310
UDI-Public(01)00643169430310(17)150523
Combination Product (Y/N)N
Initial Reporter StateNY
Initial Reporter CountryUS
PMA/510(K) Number
P130021
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2015
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Study,Health Professional,Company Representative
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 12/16/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date05/23/2015
Device Model NumberMCS-P4-23-AOA
Device Catalogue NumberMCS-P4-23-AOA
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 10/01/2025
Supplement Date Received by Manufacturer11/21/2025
Initial Report FDA Received Date10/29/2025
Supplement Report FDA Received Date12/16/2025
Date Device Manufactured06/02/2014
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
NO.
Outcome Attributed to Adverse Event Required Intervention; Hospitalization;
Patient Age89 YR
Patient SexFemale
Patient Weight45 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-